These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

224 related items for PubMed ID: 17956613

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Peptidic boronic acids are potent cell-permeable inhibitors of the malaria parasite egress serine protease SUB1.
    Lidumniece E, Withers-Martinez C, Hackett F, Collins CR, Perrin AJ, Koussis K, Bisson C, Blackman MJ, Jirgensons A.
    Proc Natl Acad Sci U S A; 2021 May 18; 118(20):. PubMed ID: 33975947
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The proteasome: a novel target for anticancer therapy.
    Montagut C, Rovira A, Albanell J.
    Clin Transl Oncol; 2006 May 18; 8(5):313-7. PubMed ID: 16760005
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Bik/NBK accumulation correlates with apoptosis-induction by bortezomib (PS-341, Velcade) and other proteasome inhibitors.
    Zhu H, Zhang L, Dong F, Guo W, Wu S, Teraishi F, Davis JJ, Chiao PJ, Fang B.
    Oncogene; 2005 Jul 21; 24(31):4993-9. PubMed ID: 15824729
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
    Li X, Wood TE, Sprangers R, Jansen G, Franke NE, Mao X, Wang X, Zhang Y, Verbrugge SE, Adomat H, Li ZH, Trudel S, Chen C, Religa TL, Jamal N, Messner H, Cloos J, Rose DR, Navon A, Guns E, Batey RA, Kay LE, Schimmer AD.
    J Natl Cancer Inst; 2010 Jul 21; 102(14):1069-82. PubMed ID: 20505154
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Tyrosine kinase inhibitors: New class of antimalarials on the horizon?
    Pathak V, Colah R, Ghosh K.
    Blood Cells Mol Dis; 2015 Aug 21; 55(2):119-26. PubMed ID: 26142327
    [Abstract] [Full Text] [Related]

  • 15. Antitumor activity of the investigational proteasome inhibitor MLN9708 in mouse models of B-cell and plasma cell malignancies.
    Lee EC, Fitzgerald M, Bannerman B, Donelan J, Bano K, Terkelsen J, Bradley DP, Subakan O, Silva MD, Liu R, Pickard M, Li Z, Tayber O, Li P, Hales P, Carsillo M, Neppalli VT, Berger AJ, Kupperman E, Manfredi M, Bolen JB, Van Ness B, Janz S.
    Clin Cancer Res; 2011 Dec 01; 17(23):7313-23. PubMed ID: 21903769
    [Abstract] [Full Text] [Related]

  • 16. Therapeutic landscape of carfilzomib and other modulators of the ubiquitin-proteasome pathway.
    Mitsiades CS.
    J Clin Oncol; 2015 Mar 01; 33(7):782-5. PubMed ID: 25605842
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Inhibitory Mechanisms of DHA/CQ on pH and Iron Homeostasis of Erythrocytic Stage Growth of Plasmodium Falciparum.
    Tang T, Xu W, Ma J, Wang H, Cui Z, Jiang T, Li C.
    Molecules; 2019 May 20; 24(10):. PubMed ID: 31137574
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Acquisition of a multidrug-resistant phenotype with a proteasome inhibitor in multiple myeloma.
    Gutman D, Morales AA, Boise LH.
    Leukemia; 2009 Nov 20; 23(11):2181-3. PubMed ID: 19516276
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.